Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers

被引:21
|
作者
Gabriel, Laurence [1 ]
Tod, Michel [2 ,3 ]
Goutelle, Sylvain [1 ,2 ,4 ]
机构
[1] Hop Geriatr Pierre Garraud, Hosp Civils Lyon, Serv Pharmaceut, 136 Rue Commandant Charcot, F-69322 Lyon 05, France
[2] Univ Lyon 1, ISPB Fac Pharm Lyon, Lyon, France
[3] Hop Croix Rousse, Serv Pharmaceut, Hosp Civils Lyon, Lyon, France
[4] Univ Lyon 1, UMR CNRS 5558, Lab Biometrie & Biol Evolut, Lyon, France
关键词
DOSE-DEPENDENT INHIBITION; IN-VIVO; POTENT INHIBITOR; CYTOCHROME-P450; 1A2; THEOPHYLLINE PHARMACOKINETICS; STEREOSELECTIVE DISPOSITION; INCREASES CONCENTRATIONS; ORAL-CONTRACEPTIVES; GENERAL FRAMEWORK; LIVER-MICROSOMES;
D O I
10.1007/s40262-016-0371-x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A simple method to predict drug-drug interactions mediated by cytochrome P450 enzymes (CYPs) on the basis of in vivo data has been previously applied for several CYP isoforms but not for CYP1A2. The objective of this study was to extend this method to drug interactions caused by CYP1A2 inhibitors and inducers. First, initial estimates of the model parameters were obtained using data from the literature. Then, an external validation of these initial estimates was performed by comparing model-based predicted area under the concentration-time curve (AUC) ratios with observations not used in the initial estimation. Third, refined estimates of the model parameters were obtained by Bayesian orthogonal regression using Winbugs software, and predicted AUC ratios were compared with all available observations. Finally, predicted AUC ratios for all possible substrates-inhibitors and substrates-inducers were computed. A total of 100 AUC ratios were retrieved from the literature. Model parameters were estimated for 19 CYP1A2 substrate drugs, 26 inhibitors and seven inducers, including tobacco smoking. In the external validation, the mean prediction error of the AUC ratios was -0.22, while the mean absolute error was 0.97 (37 %). After the Bayesian estimation step, the mean prediction error was 0.11, while the mean absolute error was 0.43 (22 %). The AUC ratios for 625 possible interactions were computed. This analysis provides insights into the interaction profiles of drugs poorly studied so far and can help to identify and manage significant interactions in clinical practice. Those results are now available to the community via a web tool (http://www.ddi-predictor.org).
引用
收藏
页码:977 / 990
页数:14
相关论文
共 50 条
  • [1] Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers
    Laurence Gabriel
    Michel Tod
    Sylvain Goutelle
    [J]. Clinical Pharmacokinetics, 2016, 55 : 977 - 990
  • [2] Determination of drug interactions with CYP1A2
    Volak, LP
    Meissen, JK
    Zlokarnik, G
    [J]. DRUG METABOLISM REVIEWS, 2003, 35 : 90 - 90
  • [3] Quantitative prediction of CYP1A2-mediated drug interactions
    Gabriel, L.
    Tod, M.
    Goutelle, S.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 : 12 - 12
  • [4] Quantitative prediction of oral drug interactions caused by CYP3A4 inhibition for an extended panel of substrates and inhibitors
    Loue, C.
    Tod, M.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2013, 27 : 21 - 21
  • [5] Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: Implications for in vitro prediction of drug interactions
    Karjalainen, Marjo J.
    Neuvonen, Pertti J.
    Backman, Janne T.
    [J]. DRUG METABOLISM AND DISPOSITION, 2006, 34 (12) : 2091 - 2096
  • [6] Pharmacokinetic drug interactions between abemaciclib and CYP3A inducers and inhibitors
    Kulanthaivel, Palaniappan
    Mahadevan, Daruka
    Turner, P. Kellie
    Royalty, Jane
    Ng, Wee Teck
    Yi, Ping
    Rehmel, Jessica
    Cassidy, Kenneth
    Chappell, Jill
    [J]. CANCER RESEARCH, 2016, 76
  • [7] A Disproportionality Analysis of Drug–Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)
    Lorenzo Villa-Zapata
    Ainhoa Gómez-Lumbreras
    John Horn
    Malinda S. Tan
    Richard D. Boyce
    Daniel C. Malone
    [J]. Drug Safety, 2022, 45 : 863 - 871
  • [8] Induction of CYP1A1 and CYP1A2 expressions by prototypic and atypical inducers in the human lung
    Wei, C
    Caccavale, RJ
    Weyand, EH
    Chen, S
    Iba, MM
    [J]. CANCER LETTERS, 2002, 178 (01) : 25 - 36
  • [9] Quantitative prediction of CYP2D6-mediated drug interactions
    Tod, M.
    Goutelle, S.
    Clabel-Grabit, F.
    Nicolas, G.
    Charpiat, B.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2011, 25 : 1 - 1
  • [10] A Disproportionality Analysis of Drug-Drug Interactions of Tizanidine and CYP1A2 Inhibitors from the FDA Adverse Event Reporting System (FAERS)
    Villa-Zapata, Lorenzo
    Gomez-Lumbreras, Ainhoa
    Horn, John
    Tan, Malinda S.
    Boyce, Richard D.
    Malone, Daniel C.
    [J]. DRUG SAFETY, 2022, 45 (08) : 863 - 871